A phase Ib/IIa study of AG019 for the treatment of early onset type 1 diabetes (T1D).

Trial Profile

A phase Ib/IIa study of AG019 for the treatment of early onset type 1 diabetes (T1D).

Planning
Phase of Trial: Phase I/II

Latest Information Update: 05 Apr 2018

At a glance

  • Drugs AG-019 (Primary)
  • Indications Type 1 diabetes mellitus
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors ActoBio Therapeutics
  • Most Recent Events

    • 05 Apr 2018 New trial record
    • 29 Mar 2018 According to an Intrexon Corporation media release, ActoBio Therapeutics (a wholly owned subsidiary of Intrexon Corporation), received an approval from FDA for their IND application to initiate this study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top